Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
Authors
Silviya Novakova
Hendrik Nolte (ORCID: https://orcid.org/0000-0003-1560-5099)
Oliver Pfaar (ORCID: https://orcid.org/0000-0003-4374-9639)
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
Silviya Novakova, Hendrik Nolte, Oliver Pfaar, Ján Mikler et al.
Citations
11 citations
Journal
The Lancet Regional Health - Europe
Topics
Allergic Rhinitis and Sensitization
Field-Weighted Citation Impact (FWCI)
4.21
article
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
Silviya Novakova, Hendrik Nolte, Oliver Pfaar, Ján Mikler, Antje Schuster, Davide Caimmi, Majken G. Hougaard, Andrzej Emeryk, Rémi Gagnon, Anne Sofie Østerdal
article en
11 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Regional Health - EuropeVol. 48
Institutions
Medical University of Lublin (PL), Inserm (FR), Philipps University of Marburg (DE), Université de Montpellier (FR), Düsseldorf University Hospital (DE), Centre Hospitalier Universitaire de Montpellier (FR), St.Caridad Hospital (BG), ALK-Abelló (Denmark) (DK), Ministère des Ressources naturelles et des Forêts (Québec) (CA), Martin University Hospital (SK), Heinrich Heine University Düsseldorf (DE), Comenius University Bratislava (SK)